主要文件

查看所有文档

Y0000457

瑞格列奈

Name: 瑞格列奈
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

(S)-(+)-2-乙氧基-4- [N- [1-（2-哌啶苯基）-3-甲基-1-丁基] 氨基羰基甲基] 苯甲酸, Novonorm, Prandin

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₇H₃₆N₂O₄

化学文摘社编号:

135062-02-1

分子量:

452.59

NACRES:

NA.24

PubChem Substance ID:

329830967

UNSPSC Code:

41116107

MDL number:

MFCD00906179

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

repaglinide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(O)=O

InChI

1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1

InChI key

FAEKWTJYAYMJKF-QHCPKHFHSA-N

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Repaglinide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

瑞格列奈是一种有效的短效胰岛素促分泌剂，可通过关闭胰岛β细胞质膜中的ATP敏感性钾（K_ATP）通道发挥作用。

瑞格列奈是一种有效的短效胰岛素促分泌剂，可通过关闭胰岛β细胞质膜中的ATP敏感性钾（K_ATP）通道发挥作用。它是一类新的胰岛素促分泌素，其结构上与磺酰脲无关，专为治疗2型糖尿病而开发。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 瑞格列奈

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.

Carolina Säll et al.

Drug metabolism and disposition: the biological fate of chemicals, 40(7), 1279-1289 (2012-03-28)

Repaglinide is presently recommended by the U.S. Food and Drug Administration as a clinical CYP2C8 probe, yet current in vitro and clinical data are inconsistent concerning the role of this enzyme in repaglinide elimination. The aim of the current study

Preparation, characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion.

Laxmikant Ramvallabh Zawar et al.

Chemical & pharmaceutical bulletin, 60(4), 482-487 (2012-04-03)

The influence of microwave technology on the in vitro dissolution rate and in vivo antihyperglycemic activity of a poorly water soluble drug, repaglinide (RG) was studied. Solid dispersions were prepared by conventional fusion method and microwave method using poloxamer 188.

LC-MS/MS-ESI method for simultaneous quantitation of metformin and repaglinidie in rat plasma and its application to pharmacokinetic study in rats.

Kuldeep Sharma et al.

Biomedical chromatography : BMC, 27(3), 356-364 (2012-08-07)

A highly sensitive and specific LC-MS/MS-ESI method has been developed for simultaneous quantification of metformin (MFN) and repaglinide (RGN) in rat plasma (50 μL) using phenacetin as an internal standard (IS). Simple protein precipitation was used to extract MFN and

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0000457	04061837568640